Navigation Links
Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
Date:3/19/2012

LEXINGTON, Mass., March 19, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease.  Avaxia Biologics has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH) to support the development of a novel antibody therapeutic for inflammatory bowel disease. This Phase II award provides Avaxia with $1.5 million in funding over 2 years and was based on the successful completion of a Phase I SBIR award that demonstrated efficacy of AVX-470 in mouse model systems of inflammatory bowel disease.

"We are delighted to have been awarded this grant from the NIH, and we thank the NIH for funding the further safety and efficacy testing of AVX-470 that will pave the way towards clinical trials," said Barbara S. Fox, Avaxia's founder and CEO.  "Our in vivo animal data, generated under prior funding of the NIH, has shown that our orally active anti-TNF antibody significantly reduced inflammatory bowel disease severity in three different animal models and showed superior efficacy to an oral steroid drug in a comparative test of disease remission. 

"We believe these consistent and statistically significant results in the standard animal models of IBD indicate that AVX-470 has the potential to become a leading therapy for inflammatory bowel disease, a chronic and debilitating disease of over a million and a half North Americans and four million people worldwide.  We are also heartened to observe that our product has shown superior efficacy to an oral steroid drug in a comparative test of disease remission.  With these impressive results, and with the support of this Phase II SBIR grant, Avaxia plans to enter into clinical trials with AVX-470 in patients with IBD this year.  AVX-470 appears to be on track to be the first orally-active anti-TNF antibody for IBD."

About Inflammatory Bowel Diseases:  Inflammatory bowel diseases incur significant personal and societal costs. For example, the primary symptoms of both Crohn's disease and ulcerative colitis are abdominal pain, diarrhea and bleeding. These diseases typically present at a young age, and most patients require lifelong therapy. Chronic drug therapy, hospitalization, and surgery are common and are associated with significant morbidity.  The Centers for Disease Control (CDC) estimates that 1.4 million people in the U.S. suffer from these diseases, with an overall annual health care cost of more than $1.7 billion.  The prevalence of IBD is equally divided between Crohn's disease and ulcerative colitis.

About Avaxia Biologics, Inc.: Avaxia Biologics is a development-stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, GI acute radiation syndrome, celiac disease, oral mucositis, diabetes and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics Barbara Fox Named one of Mass High Techs Women to Watch in 2012
2. Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
3. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
4. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
5. Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Companys Synthetic Biologics Strategic Focus
6. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
7. Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development
8. BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
9. Treatment of Patients With Malignant Mesothelioma Utilizing Photodynamic Therapy With Pinnacle Biologics Compound PHOTOFRIN® - Obtains FDA Orphan Drug Designation
10. ResearchMoz: Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)
11. US Biologics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
(Date:10/4/2017)... Oct. 4, 2017  According to the Centers for Disease Control and ... October . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the ... certain health insurance regulations. ... time to get a flu shot is by the end of October, ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
Breaking Medicine News(10 mins):